Horizon Therapeutics Public Profit Margin 2009-2021 | HZNP

Current and historical gross margin, operating margin and net profit margin for Horizon Therapeutics Public (HZNP) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Horizon Therapeutics Public net profit margin as of September 30, 2021 is 18.66%.
Horizon Therapeutics Public Annual Profit Margins
Horizon Therapeutics Public Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $23.154B $2.200B
Horizon Therapeutics PLC is a biopharmaceutical company. It is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines which address unmet medical needs. The Company markets medicines through its orphan, rheumatology and primary care business units. Horizon Therapeutics PLC, formerly known as Horizon Pharma Public Limited Company, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95